Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by New York University School of Medicine.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00883272
First received: April 16, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
  Purpose

The purpose of this study is to determine if Femeralle (DT56a) has an effect on the coagulation system, measured by platelet adhesion and aggregation, of normal and thrombophilic postmenopausal women.


Condition Intervention
Menopause
Thrombophilia
Dietary Supplement: DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Assessment of Femarelle (DT56a), a Novel SERM, Effect on the Clotting Time in Normal and Thrombophililic Postmenopausal Women

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • The PFA-100 (Dade Behring, Inc.) device was used to evaluate platelet adhesion and aggregation. Clotting time (sec.) was recorded and defined as the time for blood to block a collagen membrane coated with epinephrine (CEPI) or ADP (CADP). [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples Without DNA

Blood samples were collected in evacuated tubes (Vacutainer, Becton Dickinson) at baseline, eight weeks, and one year.


Enrollment: 32
Study Start Date: January 2007
Estimated Study Completion Date: June 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Normal Controls
25 women with CADP-CT > 66 seconds were treated with Femarelle
Dietary Supplement: DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]
a unique enzymatic isolate of the active complex in Tofu
Thrombophilic
Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT < 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
Dietary Supplement: DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]
a unique enzymatic isolate of the active complex in Tofu

Detailed Description:

Women using hormone therapy (HT) are at an increased relative risk of venous thromboembolism (VTE). The frequency of inherited Factor V Leiden and other risk factors for VTE in the general population is estimated at 5-10%. This population has a 5-21 fold greater risk to develop VTE. Therefore, given the high thrombotic risk for the combination of hormone use and hereditary prothrombotic abnormalities these women's symptoms frequently go untreated for lack of alternative therapies. DT56a (Femarelle) is a soy derived compound that has been shown to act as a novel selective estrogen receptor modulator (SERM) in the alleviation of menopausal symptoms and prevention of postmenopausal bone loss without effecting the endometrium or the sex hormone blood profile. The research question of the current study is to assess the effect of femeralle on the coagulation system and determine if it is a reasonable and safe alternative for the treatment of menopausal symptoms in thrombophilic women.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Peri- and postmenopausal women aged 40-67. Menopause defined as a FSH > 40 and no menses for > 1 year.

Criteria

Inclusion Criteria:

  • No previous exogenous estrogen exposure
  • Symptomatic Menopause: hot flashes, sleep disturbance, or other symptoms related to estrogen deficiency
  • Menopausal (see above)

Exclusion Criteria:

  • History of bleeding or thrombotic disorder
  • History of malignancy (particularly Breast Cancer)
  • Diabetics
  • Coronary Artery Disease
  • Liver Disease
  • Concurrent Anticoagulation therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00883272

Locations
United States, New York
251 East 33rd Street
New York, New York, United States, 10016
Sponsors and Collaborators
New York University School of Medicine
Investigators
Principal Investigator: Lila Nachtigall, MD New York University School of Medicine
  More Information

Publications:
Responsible Party: Rebecca Hope Jessel, MSIII, NYU School of Medicine, Department of Obstetrics and Gynecology
ClinicalTrials.gov Identifier: NCT00883272     History of Changes
Other Study ID Numbers: 03-0670-0
Study First Received: April 16, 2009
Last Updated: April 16, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by New York University School of Medicine:
Menopause
Thrombophilia
factor V Leiden
Estrogen Replacement Therapy
Hypercoagulability
Venous Thrombosis

Additional relevant MeSH terms:
Thrombophilia
Hematologic Diseases

ClinicalTrials.gov processed this record on April 17, 2014